Nick Cannon said he and the mother of his 5-month-old son who died of brain cancer decided not to treat the infant with any invasive treatments, instead opting to give him the most comfortable life — however short it might be. "We started asking, ‘Is there a way to...
Nick Cannon is opening up to People about the unimaginable loss of his son Zen at just 5 months old. Zen, his son with Alyssa Scott, was diagnosed with a brain tumor at 2 months, and died December 5. Nick explained that he and Alyssa were concerned about Zen’s breathing...
Nick Cannon is shedding more light on the final weeks of life for his late son, Zen, who was diagnosed with a high-grade glioma, a rare and aggressive form of brain cancer, at just 2 months old. "We started asking, 'Is there a way to prevent this? If not, how...
Drugs developed to treat AIDS and HIV could offer hope to patients diagnosed with the most common form of primary brain tumor. The breakthrough, co-funded by the charity Brain Tumor Research, is significant because, if further research is conclusive, the anti-retroviral drugs could be prescribed for patients diagnosed with meningioma and acoustic neuroma brain tumors (also known as schwannoma).
Matthew G. Vander Heiden, MD, PhD, former Damon Runyon Innovator and current mentor, says he gets a lot of questions from his cancer patients about how their diet might impact disease progression. Often, these patients have heard the hypothesis that an aggressively calorie-restricted diet or the low-carbohydrate, high-fat ketogenic diet may slow tumor growth. The logic for these diets is that cancer cells require high levels of glucose to fuel their rapid proliferation, so depriving them of sugar might throw a wrench in the works. However, as Damon Runyon Fellow Evan C. Lien, PhD, a postdoc in Dr. Vander Heiden’s lab at MIT, put it: “A lot of the advice out there isn’t necessarily based on very good science.”
Following an orphan drug designation earlier in 2021, NUV-422 has been granted a fast track designation for the treatment of high-grade gliomas. An investigational cyclin-dependent kinase (CDK) 2/4/6 inhibitor, NUV-422, was granted an FDA fast track designation for the treatment of patients with high-grade gliomas, including glioblastoma multiforme, according to a press release by Nuvation Bio Inc.1.
YOU MAY ALSO LIKE
The fashion world was in shock following the passing of fashion designer Virgil Abloh at the age of 41, after a 2-year private battle with cardiac angiosarcoma, a rare cancer. Abloh first came to prominence when he was hired by Kanye West to design tour merchandise and album art. In 2013, he founded his own fashion label, Off-White, a line of high-end streetwear. The line became a favorite of celebrities such as Khloé Kardashian, Naomi Campbell, Bella Hadid, and Rihanna, as well as many others.
Nick Cannon, who revealed on his daytime talk show earlier this month that his and Alyssa Scott's 5-month-old son Zen had died of brain cancer, says: "My heart is shattered. I wish I could have done more, spent more time with him, taken more pictures. I wish I could have hugged him longer."
Swedish recently announced a $20 million personal bequest from Paul G. Allen, philanthropist and co-founder of Microsoft. The gift, made shortly after his death in 2018, supports the creation of the Paul G. Allen Research Center at Swedish. “It’s really given us an amazing opportunity to change the future for...
City of Hope, a world-renowned cancer research and treatment organization, today announced study results of a Phase 2 clinical trial showing monotherapy with sotorasib resulted in anti-tumor activity and a favorable benefit-risk profile among heavily pretreated patients with advanced colorectal cancer. The research was published today in Lancet Oncology. Colorectal...
Updated findings from the phase 1/2 TRIDENT-1 trial evaluating repotrectinib showed efficacy in patients with neurotrophic tyrosine receptor kinase fusion-positive advanced solid tumors in expanded cohorts. Updated findings from the phase 1/2 TRIDENT-1 trial (NCT03093116) evaluating repotrectinib showed efficacy in patients with neurotrophic tyrosine receptor kinase (NTRK) fusion–positive advanced solid...
Might brushing your teeth protect against cancer? The suggestion looks like it belongs in the pages of an unreliable tabloid, but scientific evidence for the link is strong and growing. Take head and neck cancer, which kills some 450,000 people worldwide every year. It’s associated with smoking and drinking alcohol,...
Mount Sinai researchers have solved a major mystery in cancer research: How cancer cells remain dormant for years after they leave a tumor and travel to other parts of the body, before awakening to create metastatic cancer. According to findings reported in Nature Cancer in December, the cells remain quiet...
PRESQUE ISLE, Maine (WAGM) - The holidays are here and with that comes many holiday traditions...one of those traditions is Christmas lights. But while many find them beautiful to look at, for others, they can negatively effect their health. It’s today Medical Monday. Brian Adrian, a primary care physician...
Nature World News
Medical experts in the United States believe to have discovered why persons with respiratory problems appear to always have reduced neurological disorders. The discoveries of this study may one day aid in the development of improved therapies for both illnesses. The strange association among pneumonia and tumors initially appeared in...
Mast cell tumors are a cancerous condition of the body’s mast cells. They are more common in dogs than cats, and more common in older animals than younger animals. Mast cell tumors can be very aggressive and fast-growing, but they are also responsive to treatment. The goal of any treatment is to remove or shrink the tumor before it spreads too far into other tissues or organs.
Driving up the immune response at the site of a cancer tumor with nanotechnology may help enhance immunotherapy treatments in advanced stages of the disease, new research in mice suggests. In mouse models of numerous types of cancer, scientists boosted activation of T cells, important fighters in an immune response,...
Most never smokers who develop lung cancer have tumor mutations that make them eligible for precision medicine, according to a recent study. At least 10% to 20% of people with lung cancer never smoked, and they appear to have a distinct form of the disease. (See “Finding Grace in Adversity.”). One difference is that it occurs more often in women. Another is that patients are more likely to have so-called driver mutations that spur uncontrolled cell growth—and that can be treated with targeted therapies.
Rain Therapeutics (NASDAQ:RAIN) is set to join the NASDAQ Biotechnology Index. The move is effective as of market open on December 20, 2021. Previously (Nov. 22): Dosing underway in Rain Therapeutics' mid-stage milademetan trial for advanced solid tumors.
Editas Medicine (NASDAQ:EDIT) is trading 6.79% premarket after reporting positive preclinical data showing that its proprietary AsCas12a gene editing was able to reduce solid tumors. The in vitro and in vivo data was presented at the 63rd American Society of Hematology Annual Meeting. It used two modified induced pluripotent stem...